Cormorant Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q2 | – | Sell |
-75,000
| Closed | -$5.08M | – | 75 |
|
|
2017
Q1 | $5.08M | Sell |
75,000
-35,842
| -32% | -$2.43M | 0.74% | 42 |
|
|
2016
Q4 | $7.79M | Hold |
110,842
| – | – | 1.05% | 29 |
|
|
2016
Q3 | $7.86M | Hold |
110,842
| – | – | 0.87% | 39 |
|
|
2016
Q2 | $5.42M | Buy |
110,842
+1,342
| +1% | +$65.6K | 0.77% | 41 |
|
|
2016
Q1 | $6.93M | Hold |
109,500
| – | – | 1.04% | 33 |
|
|
2015
Q4 | $12.3M | Hold |
109,500
| – | – | 1.47% | 27 |
|
|
2015
Q3 | $10.5M | Buy |
109,500
+7,500
| +7% | +$722K | 1.68% | 20 |
|
|
2015
Q2 | $10.4M | Hold |
102,000
| – | – | 1.39% | 23 |
|
|
2015
Q1 | $6.33M | Sell |
102,000
-18,000
| -15% | -$1.12M | 0.98% | 32 |
|
|
2014
Q4 | $5.27M | Hold |
120,000
| – | – | 0.81% | 34 |
|
|
2014
Q3 | $6.79M | Hold |
120,000
| – | – | 1.4% | 19 |
|
|
2014
Q2 | $5.39M | Buy |
120,000
+60,000
| +100% | +$2.69M | 1.43% | 27 |
|
|
2014
Q1 | $2.93M | Buy |
+60,000
| New | +$2.93M | 0.67% | 43 |
|